Marijuana use not linked to eGFR changes, albuminuria
High levels of marijuana exposure appears to not be longitudinally associated with prevalent albuminuria and substantial changes in estimated glomerular filtration rate by cystatin C (eGFRcys), a recent US epidemiological study has shown.
The researchers recruited 3,765 adolescents with preserved eGFR and whose cystatin C levels and urinary albumin-to-creatinine ratios were measured at defined intervals. Marijuana use was assessed at defined intervals using a self-administered questionnaire.
Over the 10-year follow-up, 83 percent (n=3,131) of the participants reported either past or current marijuana use, with the mean eGFRcys measured to be 111 mL/min per 1.73 m2. Throughout the duration of the study, the proportion of current marijuana use remained above 15 percent.
Participants with at least 5 years of marijuana use had significantly lower eGFRcys, according to a multivariable analysis adjusted for age, race, sex, employment status, comorbidities and other clinical factors (percent difference, -3.0; 95 percent CI, -5.6 to -0.4; p=0.03).
While the trend between greater marijuana use and lower eGFRcys was statistically significant in the overall sample (p=0.04) and when stratified by race (p=0.03), no dose-response relationship was observed.
In contrast, marijuana use, even in those with at least 5 years of use, was not associated with 5-year changes in eGFRcys, both from years 10 to 15 and 15 to 20 (p=0.82 for trend).
Similarly, both rapid declines in eGFRcys (p=0.66 for trend) and prevalent albuminuria (p=0.41 for trend) were not associated with higher levels of marijuana use.